Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novonesis (Novozymes) BNVZMF +2.08%90 Equity-to-Asset is 0.67 as of Jun. 2026, which is 22% above its 10-year median of 0.55. GuruFocus rates NVZMF with a GF Score™ of 90/100 and a GF Value™ of $63.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,624 Chemicals companies, Novonesis (Novozymes) B ranks better than 62.87% on this metric.
Novonesis (Novozymes) B (OTCPK:NVZMF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Novonesis (Novozymes) B Equity-to-Asset Related Terms
Novonesis (Novozymes) B Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NVZMF vs LIN, SHW, ECL: Equity-to-Asset Comparison
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B Equity-to-Asset vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's Equity-to-Asset falls into.
Novonesis (Novozymes) B Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Novonesis (Novozymes) B's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (NVZMF) has a Equity-to-Asset of 0.67 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Novonesis (Novozymes) B and its competitors. This is 22% above median its historical median of 0.55. Over the past decade, Novonesis (Novozymes) B's Equity-to-Asset has ranged from 0.45 to 0.75. According to the industry distribution chart, Novonesis (Novozymes) B ranks #603 out of 1624 companies in the Chemicals industry, placing it in the top 37.1%.
Is Novonesis (Novozymes) B's Equity-to-Asset too high?
Novonesis (Novozymes) B's current Equity-to-Asset of 0.67 is 22% above median its 10-year median of 0.55. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 0.75. The Chemicals industry median Equity-to-Asset is 0.60. Novonesis (Novozymes) B's value of 0.67 is 11.7% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #603 out of 1624 companies in the Chemicals industry, which is above the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Equity-to-Asset compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #603 out of 1624 companies for Equity-to-Asset. This puts Novonesis (Novozymes) B in the upper half of its industry. The industry median Equity-to-Asset is 0.60. Novonesis (Novozymes) B's value of 0.67 is 11.7% above this benchmark. Historically, Novonesis (Novozymes) B's own Equity-to-Asset has ranged from 0.45 to 0.75 over the past decade. While the company's 10-year median is 0.55 vs. the industry median of 0.60, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Chemicals company?
The median Equity-to-Asset among Chemicals companies is 0.60, based on 1,624 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current Equity-to-Asset of 0.67 is 11.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current Equity-to-Asset is 0.67, which is 22% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $63.82, compared to a current price of $66.44 — trading 4.1% above its estimated fair value. The current Equity-to-Asset is 0.67, which is 22% above median its 10-year median of 0.55 and 11.7% above the Chemicals industry median of 0.60. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current Equity-to-Asset is 0.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued.
The current stock price of $66.44 is trading 4.1% above its estimated GF Value™ of $63.82.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
Key valuation signals for NVZMF:
Equity-to-Asset: 0.67 (22% above median its 10-year median of 0.55)
GF Value™: $63.82 vs. price of $66.44 (4.1% above fair value)
Industry Position: 11.7% above the Chemicals median (#603 of 1624)
No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis (Novozymes) B is a Danish biotechnology company formed in 2024 through the merger of Novozymes and Chr. Hansen. It is a leading global producer of industrial enzymes and microbial solutions, serving industries such as household care, food and beverages, bioenergy, agriculture and animal feed, and technical and pharmaceutical applications. Its biological products help customers improve yield, efficiency, and performance while reducing energy use and waste. The company operates across two main business areas: enzymes and microorganisms, spanning food and health biosolutions and agriculture, bioenergy, and technical biosolutions. Headquartered in Denmark, Novonesis employs more than 11,000 people and operates numerous research, development, and application centers alongside manufacturing sites worldwide. Revenue is generated primarily through the sale of enzyme and microbial products to industrial and agricultural customers globally, supported by ongoing research and application development.
90GF Score
Get the complete analysis for NVZMF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVZMF has been successfully added to your 
